Phase 1/2a Clinical Trials of Bi-1206, a Monoclonal Antibody to Fcγriib, Administered as a Single Agent or in Combination With Rituximab in Subjects With B-Cell Malignancies
Hematological Oncology - United Kingdom
doi 10.1002/hon.206_2631
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley